JP Morgan Chase Portfolio holdings
JPMorgan Chase & Co., formed by the 2000 merger of J.P. Morgan & Co. and Chase Manhattan Bank, is a global financial services giant headquartered in New York City, tracing its roots back to 1799 through its predecessor firms. As one of the largest banks in the world, it operates across investment banking, commercial banking, asset management, and consumer banking, managing trillions in assets and serving millions of customers, corporations, and governments. Led by CEO Jamie Dimon since 2005, the firm is renowned for its role in high-profile deals, robust trading operations, and its Chase retail banking network, which includes extensive credit card and mortgage services. Combining a legacy of financial innovation with a dominant market presence, JPMorgan Chase remains a cornerstone of the global economy.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
JPMorgan BetaBuilders Europe ETF
BBEU
|
+$5.47B |
| 2 |
iShares 0-1 Year Treasury Bond ETF
SHV
|
+$3.17B |
| 3 |
State Street Financial Select Sector SPDR ETF
XLF
|
+$2.05B |
| 4 |
Amazon
AMZN
|
+$1.96B |
| 5 |
Meta Platforms (Facebook)
META
|
+$1.6B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$1.72B |
| 2 |
Vanguard Intermediate-Term Treasury ETF
VGIT
|
+$1.31B |
| 3 |
UnitedHealth
UNH
|
+$1.26B |
| 4 |
Automatic Data Processing
ADP
|
+$1.17B |
| 5 |
Alphabet (Google) Class A
GOOGL
|
+$1.08B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 27.28% |
| 2 | Technology | 17.17% |
| 3 | Healthcare | 10.79% |
| 4 | Financials | 9.36% |
| 5 | Consumer Discretionary | 8.67% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
BCIC
4576
BCP Investment Corp
BCIC
$85.7M
| $309K | ﹤0.01% |
+14,991
| New | +$334K |
2023 Q1
0 quarters
|
|
4577
CALL
BridgeBio Pharma
BBIO
$13.1B
| $308K | ﹤0.01% |
+18,600
| New | +$217K |
2023 Q1
0 quarters
|
|
4578
MiMedx Group
MDXG
$674M
| $308K | ﹤0.01% |
90,265
+21,131
| +31% | +$81.8K |
2020 Q4
9 quarters
|
|
4579
Fidelity Quality Factor ETF
FQAL
$1.44B
| $306K | ﹤0.01% |
6,455
+5,374
| +497% | +$249K |
2022 Q4
1 quarter
|
|
4580
ClearPoint Neuro
CLPT
$336M
| $306K | ﹤0.01% |
36,218
+1,719
| +5% | +$15.1K |
2019 Q3
14 quarters
|
|
|
MUI
4581
DELISTED
BlackRock Municipal Income Fund, Inc.
MUI
| $306K | ﹤0.01% |
+26,237
| New | +$305K |
2023 Q1
0 quarters
|
|
4582
FRP Holdings
FRPH
$389M
| $305K | ﹤0.01% |
10,556
+2,568
| +32% | +$72.4K |
2017 Q4
21 quarters
|
|
4583
CALL
Baxter International
BAX
$12.6B
| $304K | ﹤0.01% |
7,500
| – | – |
2022 Q4
1 quarter
|
|
4584
CNB Financial Corp
CCNE
$1B
| $304K | ﹤0.01% |
15,846
-1,090
| -6% | -$24.9K |
2017 Q4
21 quarters
|
|
4585
Porch Group
PRCH
$1.95B
| $304K | ﹤0.01% |
212,730
-80,758
| -28% | -$191K |
2021 Q2
7 quarters
|
|
4586
Shore Bancshares
SHBI
$756M
| $304K | ﹤0.01% |
21,270
+2,580
| +14% | +$42.9K |
2021 Q4
5 quarters
|
|
4587
Fidelity MSCI Utilities Index ETF
FUTY
$2.19B
| $304K | ﹤0.01% |
6,930
-7,442
| -52% | -$327K |
2022 Q4
1 quarter
|
|
4588
Axogen
AXGN
$2.13B
| $302K | ﹤0.01% |
31,951
+8,039
| +34% | +$73.5K |
2017 Q4
21 quarters
|
|
|
MREO
4589
Mereo BioPharma
MREO
$55.9M
| $302K | ﹤0.01% |
427,133
+281,874
| +194% | +$254K |
2021 Q3
6 quarters
|
|
|
LAC
4590
DELISTED
Lithium Americas Corp. Common Shares
LAC
| $302K | ﹤0.01% |
13,859
-48,784
| -78% | -$1.08M |
2021 Q1
8 quarters
|
|
4591
NewAmsterdam Pharma
NAMS
$2.66B
| $301K | ﹤0.01% |
22,367
+21,265
| +1,930% | +$268K |
2022 Q4
1 quarter
|
|
4592
Covenant Logistics
CVLG
$840M
| $300K | ﹤0.01% |
16,930
-108,690
| -87% | -$1.88M |
2016 Q4
25 quarters
|
|
4593
GCM Grosvenor
GCMG
$806M
| $300K | ﹤0.01% |
38,504
+13,657
| +55% | +$113K |
2021 Q2
7 quarters
|
|
|
MOFG
4594
DELISTED
MidWestOne Financial Group
MOFG
| $300K | ﹤0.01% |
12,251
-3,646
| -23% | -$108K |
2016 Q4
25 quarters
|
|
4595
Tejon Ranch
TRC
$441M
| $300K | ﹤0.01% |
16,427
+3,774
| +30% | +$72.5K |
2015 Q4
29 quarters
|
|
4596
PIMCO 25+ Year Zero Coupon US Treasury Index Exchange-Traded Fund
ZROZ
$1.85B
| $300K | ﹤0.01% |
3,136
+497
| +19% | +$46.7K |
2022 Q3
2 quarters
|
|
|
DAWN
4597
DELISTED
Day One Biopharmaceuticals
DAWN
| $297K | ﹤0.01% |
22,211
-49,795
| -69% | -$973K |
2021 Q2
7 quarters
|
|
|
ESPR
4598
DELISTED
Esperion Therapeutics
ESPR
| $297K | ﹤0.01% |
186,795
-189,051
| -50% | -$976K |
2015 Q3
30 quarters
|
|
4599
Veru
VERU
$42.1M
| $296K | ﹤0.01% |
25,525
+15,824
| +163% | +$641K |
2018 Q1
20 quarters
|
|
4600
State Street SPDR Bloomberg Investment Grade Floating Rate ETF
FLRN
$3.06B
| $294K | ﹤0.01% |
9,675
-184,781
| -95% | -$5.63M |
2017 Q1
24 quarters
|
|
Similar funds
JP Morgan Chase's Q1 2023 Portfolio in Review
As of Q1 2023, JP Morgan Chase held 7,579 positions worth $821B, up 8.2% from $759B the previous quarter. Its ten largest holdings account for 17% of the portfolio.
JP Morgan Chase's Q1 2023 filing shows 751 new, 3,314 increased, 2,056 reduced and 652 closed positions. Its largest new stake was Near Intelligence, Inc. Common Stock: 5,852,099 shares worth $14.7M. The largest sale was Eli Lilly, an estimated $1.72B.
By sector, the portfolio is most concentrated in Miscellaneous at 27% of assets, up from 27% a quarter earlier, followed by Technology and Healthcare.
- JP Morgan Chase's largest Q1 2023 buy was Near Intelligence, Inc. Common Stock: 5,852,099 shares worth $14.7M.
- JP Morgan Chase added most to JPMorgan BetaBuilders Europe ETF in Q1 2023, an estimated $5.47B increase.
- JP Morgan Chase's biggest Q1 2023 reduction was Eli Lilly, cutting an estimated $1.72B.
- JP Morgan Chase fully exited IAA, Inc. Common Stock in Q1 2023, selling an estimated $155M.
- JP Morgan Chase's ten largest holdings make up 17% of its $821B portfolio in Q1 2023.
- JP Morgan Chase opened 751 new positions and closed 652 in Q1 2023.
- JP Morgan Chase's portfolio value rose 8.2% quarter-over-quarter to $821B.
Based on JP Morgan Chase's 13F filing for Q1 2023, filed 11 May 2023.